NEURORADIOLOGY / GUIDELINES / RECOMMENDATIONS
Recommendations of the Polish Medical Radiological Society regarding MRI in patients with plexiform neurofibromas in the course of neurofibromatosis type 1
More details
Hide details
1
Faculty of Medical Sciences, Bydgoszcz University of Science and Technology, Bydgoszcz, Poland
2
Department of Diagnostic Imaging, Radiology and Nuclear Medicine, Faculty of Medical Science in Katowice, Medical University of Silesia in Katowice, Poland
3
Department of Radiology and Diagnostic Imaging, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland
4
Department of Diagnostic Imaging, Institute of Mother and Child, Warsaw, Poland
5
Department of Radiology, Polish-American Institute of Paediatrics, Jagiellonian University, Krakow, Poland
6
Department of Paediatric Radiology, Regional Specialised Children’s Hospital, Olsztyn, Poland
7
Division of Radiology, University of Warmia and Mazury, Olsztyn, Poland
8
Department of Diagnostic Imagining, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland
9
Department of General Radiology, Interventional Radiology, and Neuroradiology, Wroclaw Medical University, Wroclaw, Poland
10
Coordinated Medical Care Centre for Neurofibromatoses and Related RASopathies, Department of Paediatrics, Haematology, and Oncology, Medical University of Warsaw, Warsaw, Poland
11
Department of Paediatric Oncology and Haematology, Institute of Paediatrics, Jagiellonian University Medical College, Krakow, Poland
12
Department of Paediatric Haematology and Oncology, Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
Submission date: 2025-03-13
Acceptance date: 2025-03-16
Publication date: 2025-06-03
Corresponding author
Magdalena Dagmara Machnikowska-Sokołowska
Department of Diagnostic Imaging, Radiology and Nuclear Medicine, Faculty of Medical Science
in Katowice, Medical University of Silesia in Katowice, 16 Medyków St., 40-752 Katowice, Poland
Pol J Radiol, 2025; 90: 286-291
KEYWORDS
TOPICS
ABSTRACT
Neurofibromatosis type 1 (NF1) is a genetically determined disorder with a complex clinical picture, including disorders of many systems and organs, that predisposes to the development of various cancers. Approximately 10-30% of patients with NF1 develop plexiform neurofibromas (PN), non-malignant tumours growing along the nerves, tending to infiltrate nerves and nerve plexuses, and may grow into internal organs, the spinal canal, and middle ear, deforming bones and various regions of the body. Magnetic resonance imaging (MRI) plays a key role in the management of individuals during the course of PN, as a screening tool at baseline, for surveillance (in individuals with known PN), to evaluate treatment response, and for preoperative assessment for surgical planning. The practical recommendations presented in this article aim to standardise the protocol for MRI examination of PN in the course of NF1 for the purpose of treatment in a clinical program in Poland. The protocol, covering volumetric MRI examination, imaging schedule, determination of the target change, the technique for measuring the volume of lesions, and suspected malignant transformation, is intended to be the minimum set of MRI sequences and views that must be included in every examination of these patients.
REFERENCES (10)
1.
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23: 1506-1513.
2.
Cannon A, Chen MJ, Li P, Boyd KP, Theos A, Redden DT, et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J Rare Dis 2018; 13: 31. DOI: 10.1186/s13023-018-0772-z.
3.
Knight SWE, Knight TE, Santiago T, Murphy AJ, Abdelhafeez AH. Malignant peripheral nerve sheath tumors – a comprehensive review of pathophysiology, diagnosis, and multidisciplinary management. Children (Basel) 2022; 9: 38. DOI: 10.3390/children9010038.
4.
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020; 382: 1430-1442.
5.
Program lekowy B.155 „Leczenie chorych z nerwiakowłókniakami splotowatymi w przebiegu neurofibromatozy typu 1 (NF1)”. Ministerstwo Zdrowia; 2024.
6.
Fisher MJ, Blakeley JO, Weiss BD, Dombi E, Ahlawat S, Akshintala S, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol 2022; 24: 1827-1844.
7.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology 2016; 87: S31-S39.
8.
Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine 2023; 56: 101818. DOI: 10.1016/j.eclinm.2022.101818.
9.
Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013; 81: S33-S40.
10.
Liu J, Huang JN, Wang MH, Ni ZY, Jiang WH, Chung M, et al. Image-based differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Front Oncol 2022; 12: 898971. DOI: 10.3389/fonc.2022.898971.